As previously reported, TD Cowen downgraded NanoString (NSTG) to Market Perform from Outperform with a price target of $1.40, down from $6, after NanoString on Friday withdrew its FY23 guidance after 10x Genomics (TXG) won a verdict in a patent case against the company as the U.S. District Court for the District of Delaware found that NanoString’s GeoMx Digital Spatial Profiler products infringe patents licensed to 10x Genomics. The company’s prospects are less visible following this and other patent losses and pending upcoming case decisions, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NSTG:
- NanoString downgraded to Market Perform from Outperform at TD Cowen
- NanoString disagrees with jury verdict, will seek to have overturned or amended
- 10x Genomics wins patent infringement case against NanoString
- Biotech Alert: Searches spiking for these stocks today
- NanoString price target lowered to $6 from $12 at TD Cowen
